Fundraising FoxLeuko Labs
Boston, US · Founded 2017 · Delaware corporation · 6 known investors
Find your way into Leuko Labs
Sign up to see every warm intro you have to Leuko Labs
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Leuko Labs team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.
Founders & leadership
Leuko Labs was founded in 2017 by Ian Butterworth, Aurelien Bourquard, Alvaro Sanchez-Ferro, and Carlos Castro-Gonzalez.
Board
Investors · 6
How we know: Good Growth Capital's portfolio page · the company's own site · a partner's Signal profile · board seat on SEC Form D · medicaldevice-network.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: medicaldevice-network.com · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$6.2M disclosed across 2 of 4 rounds · 2019–2022
- Undisclosed amountSeries AOct 2022Source ↗
- $5MSeries ASep 2022 · 4 sources
Good Growth Capital, HTH VC, IAG Capital Partners, Nina Capital
Source ↗ - Undisclosed amountSeedJul 2019Source ↗
▶$1.2MraisedFeb 2019 · 14 investors · BiotechnologyRule 506(b)
- Carlos Castro GonzalezExecutive Officer, Director
- Ian ButterworthExecutive Officer, Director
- Amy SalzhauerDirector
- Paul HartungDirector
- Offering amount
- $1.7M
- Amount sold
- $1.2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Leuko Labs went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Leuko Labs.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $213.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Leuko Labs do?
- Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.
- Who founded Leuko Labs?
- Leuko Labs was founded by Ian Butterworth, Aurelien Bourquard, Alvaro Sanchez-Ferro, Carlos Castro-Gonzalez in 2017.
- Who are Leuko Labs's investors?
- Leuko Labs's investors include Good Growth Capital, Dorm Room, MassVentures, Nina Capital, IAG Capital Partners.
- How much funding has Leuko Labs raised?
- Leuko Labs has disclosed $6.2M raised across 2 of its 4 known rounds.
- Where is Leuko Labs headquartered?
- Leuko Labs is headquartered in Boston, US.